[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]
[vc_row][vc_column][vc_column_text] England’s Chief Medical Officer, Dame Sally Davies, recently called for making genomic testing as common as blood tests in order to usher in the era […]